Fighting the epidemic of pediatric metabolic dysfunction-associated steatotic liver disease: Role of non-invasive diagnostics and early pharmacological intervention

doi:10.4254/wjh.v18.i1.111211

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 1

This Article

(0) (0) (0)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (748)

All Articles published online

Item

Count

PDF

HTML

255

Figures (1-1)

Tables (1-2)

Sum=342

Publishing Process of This Article

Item

Count

Browse

Download

139

Sum=191

Jan 27, 2026 (publication date) through May 12, 2026

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Jan 27, 2026; 18(1): 111211
Published online Jan 27, 2026. doi: 10.4254/wjh.v18.i1.111211

Fighting the epidemic of pediatric metabolic dysfunction-associated steatotic liver disease: Role of non-invasive diagnostics and early pharmacological intervention

Nicholas Beng-Hui Ng, Andrew Anjian Sng, James Guoxian Huang

Nicholas Beng-Hui Ng, Andrew Anjian Sng, James Guoxian Huang, Department of Paediatrics, Khoo Teck Puat - National University Children’s Medical Institute, National University Health System, Singapore 119228, Singapore

Author contributions: Ng NBH and Huang JG were involved in the conception of the work, data collection, drafting of the article, critical revision of the article and final approval of the published version; Sng AA was involved in the data interpretation, drafting of the article, critical revision of the article and final approval of the published version.

Conflict-of-interest statement: Ng NBH and Sng AA have received honoraria from Novo Nordisk for involvement in lectures and advisory board work.

Corresponding author: James Guoxian Huang, Assistant Professor, Department of Paediatrics, Khoo Teck Puat - National University Children’s Medical Institute, National University Health System, 1E Kent Ridge Road NUHS Tower Block Level 12, Singapore 119228, Singapore. paehgj@nus.edu.sg

Received: June 26, 2025
Revised: September 2, 2025
Accepted: December 2, 2025
Published online: January 27, 2026
Processing time: 216 Days and 9.2 Hours

Core Tip

Core Tip: The escalating prevalence of pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) mirrors the rise in pediatric obesity. The advent of non-invasive diagnostics may allow for earlier recognition of liver fibrosis, and may prioritize the need for early pharmacological therapy. We propose an updated diagnostic and monitoring algorithm incorporating recent multi-societal statements in pediatric MASLD. The increased use of weight-loss pharmacotherapy such as glucagon-like peptide 1 receptor agonists in adolescent patients has shown efficacy in inducing weight loss, which may have potential in halting MASLD progression if instituted early in the disease course.

Ng NBH, Sng AA, Huang JG. Fighting the epidemic of pediatric metabolic dysfunction-associated steatotic liver disease: Role of non-invasive diagnostics and early pharmacological intervention. World J Hepatol 2026; 18(1): 111211 [PMID: 41640966 DOI: 10.4254/wjh.v18.i1.111211]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.